Cargando…
Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859497/ https://www.ncbi.nlm.nih.gov/pubmed/29564403 http://dx.doi.org/10.1016/j.joco.2018.01.006 |
| _version_ | 1783307834938621952 |
|---|---|
| author | Ameri, Hossein |
| author_facet | Ameri, Hossein |
| author_sort | Ameri, Hossein |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5859497 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-58594972018-03-21 Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation Ameri, Hossein J Curr Ophthalmol Article Elsevier 2018-02-16 /pmc/articles/PMC5859497/ /pubmed/29564403 http://dx.doi.org/10.1016/j.joco.2018.01.006 Text en Copyright © 2018, Iranian Society of Ophthalmology. Production and hosting by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Article Ameri, Hossein Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation |
| title | Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation |
| title_full | Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation |
| title_fullStr | Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation |
| title_full_unstemmed | Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation |
| title_short | Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation |
| title_sort | prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by rpe65 mutation |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859497/ https://www.ncbi.nlm.nih.gov/pubmed/29564403 http://dx.doi.org/10.1016/j.joco.2018.01.006 |
| work_keys_str_mv | AT amerihossein prospectofretinalgenetherapyfollowingcommercializationofvoretigeneneparvovecrzylforretinaldystrophymediatedbyrpe65mutation |